INTRODUCTION
In adults, stem cell populations and progenitors are present in virtually every organ system. Throughout life, tissues are maintained by these underlying systems of cells that repair and regenerate tissues through the generation of new cells. Modulated by hormonal and local factors, these cells move through a series of hierarchical stages and processes, originating with a rare population of upstream stem cells, and progressing into more numerous, although still rare, populations of downstream transit cells and progenitor cells ( Fig. 1) (1). The stages of a stem cell life cycle include: activation, self renewal, proliferation, migration, differentiation, and death or survival ( Fig. 2) . It is reasonable to hypothesize that factors such as gender, aging, smoking, alcohol, disease states, drugs and toxins are associated with changes in the number of stem cells and the functional parameters that determine their downstream kinetics. In vitro colony forming unit assays provide a valuable window into the number and function of stem cells and progenitor cells in various tissues. Colony forming assays identify cells that will adhere to a surface, such as tissue culture plastic, and go on to proliferate by clonal expansion to form an identifiable cluster of cells. In the case of bone marrow, this type of assay has been refined to provide insight into the concentration and prevalence of connective tissue progenitors (CTPs), including osteogenic and chondrogenic populations. With these tools it is possible to begin to methodically explore and quantify the factors that influence the number and prevalence of CTPs-and the relationship between the CTP population and the health of bone and cartilage, as well as their remodeling and repair (2). This article reviews current literature regarding factors affecting CTP populations and their downstream populations.
WHAT ARE STEM CELLS?
Stem cells, by definition, share one critical feature, which is the capacity for self-renewal. This implies that a cell division takes place, and that one or both of the resultant cells retain the phenotype and full intrinsic biological potential of the mother cell. As a result, stem cells may be expanded through symmetric cell division, in which both daughters are the same. More often, in the adult setting, stem cell populations will divide asymmetrically, producing one daughter cell that replaces the mother cell and preserves the stem cell pool from depletion, while the second cell takes on a different fate, such as proliferation and expansion to give rise to downstream progenitors and ultimately the formation of new adult tissues. A growing base of studies suggests that adult mammals retain several populations of adult stem cells and progenitor cells with the intrinsic biological potential to generate progeny that can differentiate into many endodermal, mesodermal and/or ectodermal derived mature tissues. Stem cell populations have been shown to contribute to the regeneration of skeletal and cardiac myocytes, vascular endothelial cells, lung parenchyma, hepatocyte and biliary epithelium, intestinal and skin epithelium, neuroectoderm, hematopoietic cells, and bone and cartilage ( Fig. 3) (3). The knowledge of stem cell contribution to and interactions with different tissues and organs rapidly evolves with new relevant publications coming out nearly every month. As a consequence, many classical teachings in medicine are challenged. Examples include the discovery of neural stem cells contributing to central nervous system repair, which refutes the classical teaching that the tify human osteoblastic progenitors or connective tissue progenitors. For example, the STRO-1 antibody has been developed and recognizes an antigen expressed by 7 % of nucleated bone marrow cells, including all osteoblastic and stromal cell precursors. The marker is thought to be lost near the time alkaline phosphatase is expressed. Bruder et al have reported on several antibodies recognizing human osteoblastic progenitors, including the SB-10 antibody, whose antigen corresponds to leukocyte-cell adhesion molecule (ALCAM) and appears to be expressed during early stages of osteogenic differentiation and lost during the developmental expression into differentiated phenotypes (19) . The SH2 monoclonal antibody recognizes Endoglin (CD105), which is expressed by preosteoblasts in the periosteum in vivo and in vitro cultures of human connective tissue progenitors. The availability of these markers may help to identify precursor cells from the heterogenous marrow populations in which they reside and may help to define further critical cellular events during osteogenic differentiation (3, [20] [21] [22] . In addition to antibody markers, CTPs can also be identified based on expression of mRNAs indicative of an early osteoblastic phenotype, including collagen I, AP, PTHrP, PTH1 receptor, FGF receptor 1, BMP-6, and Cbfa1.
However, in vitro functional colony analysis and alkaline phosphatase expression remains the most robust and versatile method for assessing CTP populations. In this method, bone marrow harvested by aspiration contains connective tissue progenitor cells that can be induced to express a bone phenotype in vitro as a culture. The resulting adhesive colony forming units positive for alkaline phosphatase (CFU-APs) can be used to estimate the number of osteogenic progenitors (osteogenic CTPs) in a given population ( Fig. 4 ). This gives us the ability to methodically explore and quantify these relationships and the consequent affect on bone and cartilage health, remodeling, and repair. Previous studies have demonstrated significant variation in assays of cellularity and CFU-AP prevalence from human bone marrow samples, both between individual aspirates and between individual subjects (2, 23, 24) . Most of the studies discussed in the next section used CFU assays to make their observations.
CLINICAL VARIATION IN CONNECTIVE TISSUE PROGENITOR POPULATIONS
Several factors may influence the population and behavior of osteogenic progenitors. Among those variables are age, gender, smoking habits, alcohol use, estrogen/endocrine status, pharmacologic affects, disease states, acute blood loss, disuse, irradiation, and cytokines and local factors affecting bone metabolism.
The studies discussed use both animal and human models to make their observations. It should be noted that bone marrow harvesting from humans differs significantly from bone marrow harvesting in small animals. In animals, bone marrow harvesting is usually done with open irritation of explanted bones or enzymatic digestion. Human harvesting usually involves aspiration, which is a much less vigorous of dislodging cells. The bone marrow harvested in a 2cc human aspiration will contain a mean of approximately 65 million nucleated cells derived from the bone marrow cells dislodged from the 0.1-0.3 cc volume of bone marrow in the immediate area around the tip of the aspiration needle. These cells will be derived principally from the more liquid phase of bone marrow (23) . These differences in technique may often limit the comparison of small animal studies to human clinical situations. AGE Both animal and human studies show that the cellularity of marrow and the prevalence of CTPs decrease with aging. Quarto et al showed that the number of nucleated cells harvested and CFU-AP colonies grown from these cells were significantly lower in marrow harvested from aged rats as compared to control adult rats (25) . Tsuji et al also reported that cultures of marrow from 18-month-old rats produce 70 % fewer CFUs then marrow from 6 week old animals (26) . Similarly, Brockbank et al. found a decrease in the otherwise uncharacterized fibroblastic colonies (CFU-F) in aging C57BL mice from 82 CFU-Fs per million nucleated cells at 8 weeks to 55 CFU-Fs per million at 70 weeks (27) .
Using bone marrow implanted into the kidney capsule, Kahn et al observed in vivo that the osteo- genic capacity of marrow from 24-month-old mice was markedly reduced when compared to marrow from 3-4 month old mice (28) . Age-related changes in the mitotic potential or differentiation of osteoblastic progenitors have also been suggested. Kato et al found decreased mitotic activity and decreased bone formation in calvarial osteoblasts from aging rats (29) . Roholl et al presented ultrastructural evidence suggesting that age-related bone loss in rats was related to delayed or aborted maturation of preosteoblasts into osteoblasts (30) .
Corroborating with the animal studies, Muschler et al collected samples from 57 human subjects and showed a significant age related decline in the number of nucleated cells harvested in both men and women (p = 0.002) (24) . Howard et al and Hernigou et al made the same observation with bone marrow samples from 41 and 60 human donors respectively (31, 32) . However, all three studies showed a discrepancy from the animal studies and did not find age related changes in CFU-AP prevalence (24, 31, 32) . However, the general consensus is that age does play a significant role in CTP populations and that further studies are needed to explore this relationship. GENDER Muschler et al. found that gender may play a role on connective tissue progenitors in bone marrow. Men and women differ significantly with respect to the effect of age on the total number of CFU-APs obtained in bone marrow aspirates. Data from female subjects demonstrated a significant age related decline in the number of CFU-APs per aspirate (p = 0.02). Women exhibited a trend for an age-related decline in CFU-AP prevalence (the number of CFU-APs per million nucleated marrow cells), while men exhibited a trend for an age-related increase in CFU-AP prevalence among nucleated bone marrow derived cells. Although neither of these trends rose in and of themselves to a level of statistical significance (p = 0.10 and 0.15, respectively), the slopes were significantly different (p = 0.03) (24) . Studies by Howard and Hernigou also had similar findings and confirm that relationships exist between age, gender, and CTP populations (31, 32) . SMOKING Several lines of evidence suggest a potential link between tobacco use and skeletal homeostasis, justifying consideration of tobacco use as a potential predictor. Hopper and Seeman conducted a cross-sectional study of bone density in the lumbar spine and the femoral neck in 41 pairs of female twins (33) . They found that women who smoked one pack of cigarettes each day in adulthood had, at menopause, a 5-10 % decrease in bone density in the lumbar spine. Other studies have suggested that bone formed in the presence of nicotine may have inferior biomechanic properties (34) . Nicotine has also been shown to inhibit the revascularization of cancellous bone grafts and in the healing of spinal fusions and fractures (35) . In vitro, Yuhara et al report that nico-tine stimulated alkaline phosphatase activity and increased the calcium deposition by osteoblastic cells but had the opposite effect on preosteoblastic cells (36) . A more recent in vitro study done by Lippiello et al demonstrated that exposing murine osteoblast like cells to nicotine resulted in increases in alkaline phosphatase activity and increases in total protein and collagen synthesis. Nicotine doses ranged between 12.5 ng/mL to 250 ng/mL with a correlative increase in activity with increased dosage. Another set of cells was exposed to smoke condensates in addition to equivalent nicotine concentrations with a resulting decrease in all metabolic activity (37) . Haj et al suggested that nicotine dosing effects may be biphasic, reporting that concentrations < 1 μ M/L increased osteoblast proliferation, while concentrations > 1 μ M/L decreased proliferation and increased cell death. He also noted that levels of transcription factor c-fos also increased with increasing nicotine concentrations (38) . Muschler et al collected BM samples from 62 human subjects and demonstrated that bone marrow cellularity was not influenced by current or previous tobacco use. Similarly, CFU-AP prevalence data demonstrated no effects from tobacco use. These findings argue against an influence of tobacco use on CFU-AP prevalence, intrinsic osteoblastic potential, or upstream kinetics in favor of direct pharmacological effects on existing osteoblastic cells (39) . Further studies with greater subject numbers need to be conducted on human samples to clarify the true relationship between tobacco, nicotine and CTPs.
ALCOHOL USE
Hernigou also noted a very significant decrease in progenitor cell numbers and CFUs in the anterior iliac crest bone marrow aspirates of 16 human alcoholics when compared to normal controls (40) . Pedrazzoni exposed long-term murine and human bone marrow in vitro cultures to ethanol and to acetaldehyde, the main metabolite of ethanol. In both the mice and humans, CFU formation was inhibited by 50-63 % at ethanol concentrations meant to simulate in vivo levels of alcoholics (0.04 %-0.6 % in mice and 0.02 % in humans). Acetaldehyde strongly reduced CFU formation in both mice and humans at levels between 0.004 % to 0.06 %, with the highest level resulting in complete cessation of CFU activity. They also observed bone marrow cultures from nine human chronic, non-cirrhotic alcoholics and found that CFU formation was reduced by as much as 70 ± 15 % when compared to bone marrow cultures from age-matched normal subjects (41) . Both the in vitro and in vivo findings of two separate labs strongly suggest that alcohol and its metabolites directly affect the concentration and prevalence of CTP populations.
ESTROGEN STATUS
It is well established that estrogen status affects bone metabolism. Recent studies have further investigated the mechanism of this observation using CFU-AP assays. Tobias et al observed a 30-fold increase in os-teogenic precursors based on CFU-AP assays in cells harvested from mice given 17ß-estradiol for eight days. No increase was seen in cells from mice given other varying time exposures of 17ß-estradiol, suggesting that this increase in the CTP population after estrogen may be dose dependent or transient (42) . The direct effect of ovariectomy or post menopausal estrogen loss on CTP population has not been assessed. CORTICOSTEROIDS Hernigou observed decreases in progenitor cell numbers and CFUs from the anterior iliac crest bone marrow aspirates of 14 chronic glucocorticoid steroid users (40, 43) .
DISEASE STATES
Hernigou performed CFU assays on bone marrow harvested from the anterior iliac crest of 11 patients with idiopathic osteonecrosis of the femoral head. Presumably, the anterior iliac crest is separate from the femoral head and should not be subject to local influences of the disease process. However, when a comparison of the iliac crest derived CFUs from the patient groups was made to a group of a similarly age-matched healthy control group, there was a statistically significant decrease in the number of iliac crest derived CFUs in the osteonecrosis group (40) . This suggests that local necrosis seen in the femoral head may be an indication of a more systemic process in bone and marrow.
ACUTE BLOOD LOSS
Using a rabbit that sustained a one percent of body weight blood loss, Lippiello et al. harvested and cultured bone marrow cells. When compared to nonbled rabbits, the bled rabbits showed higher CFU efficiency. Lippiello also suggested that the colony forming efficiency response of bone marrow cells to blood loss is associated with increases of a bone growth promoting circulating factor that mimics the activity of osteogenin (bone morphogenetic protein 3) (44) .
DISUSE/NON-LOAD BEARING
Basso placed the hind legs of rats in weight suspension harnesses. He observed a decrease in bone mass as well as a decrease in the number of CFUs. This implies that disuse and states of reduced load bearing, such as that experience by disabled or postoperative patients, could be associated with a change in upstream kinetics that reduces the osteogenic progenitor populations (45) . IRRADIATION Research on the effects of radiation has primarily been focused on hematopoietic stem cells. Studies have shown that irradiation reduces the number of hematopoietic stem cells and hematopoietic CFUs acutely. Presumably, since they occupy the same space as hematopoietic stem cells, CTPs would follow the same fate. However, there appears to be a recovery response as well. Experimental bone marrow ablation in animals is followed by stimulation of local bone formation in the marrow cavity and in cortical osteons (46) . Another recent study showed that in mice receiving low dose radiation at 75-mGy, there was a significant increase in hematopoietic stem cell mobilization into peripheral blood 47-72 hours post radiation (47) . This response of CTPs to low or high dose radiation is unknown. 
CYTOKINES AND FACTORS
Many growth factors and cytokines have been shown to have profound effects on the proliferation, migration, differentiation and survival of osteogenic cells and marrow derived progenitors. A review of their in vitro effects is beyond the scope of this clinical review. It can be assumed that anabolic agents that result in an increase in local or systemic bone formation (e.g. BMPs, PTH, Prostaglandin E2) have a mechanism of action that includes up regulation of the proliferation, migration, differentiation and/or survival or osteogenic CTPs (49-51, 52, 53) . However the effect of these agents on CTP populations and kinetics has not been studied directly in vivo, leaving the direct and indirect effects of these agents on CTP concentration, prevalence and kinetics in vivo largely unknown. Transgenic knock-out experiments have not illuminated selective BMP effects on bone metabolism. However, haploinsufficiency of PTHrP is associated with reduced bone density, as well as an increase in adipocyte formation in bone marrow (54) . EGF and PDGF are of note, as these two factors were shown by Simmons et al (55) to be sufficient and necessary to induce in vitro CFU-F colony formation from cultures of human marrow in a serum free environment, suggesting efficacy in the activation of colony formation. bFGF has been shown to increase proliferation of CFU-F in vitro, without compromise of osteogenic potential, highlighting its potential role as a mitogen (56) . Caplan et al showed that mesenchymal stem cells pretreated in vitro with TGF-b1 demonstrated increased CFUs and bone and cartilage formation when introduced into an in vivo rat model (57) , suggesting an effect that modified in vivo kinetic performance.
CLINICAL APPLICATIONS-STEM CELL TISSUE ENGINEERING
Since stem cells can proliferate and differentiate to maintain or regenerate connective tissues like bone and cartilage, tissue engineering of stem cells has significant implications clinically. Stem cell engineering in orthopaedics is already in practice and is continually advancing. Successful tissue engineering using CTPs requires the understanding of three variables. First, a sufficient number of CTPs must be available, either at the native site or on the implant. Second, the environment needs to allow for the attachment, proliferation, migration, and differentiation of the CTPs. If an engineered matrix or material provides this property, it is considered osteoconductive. Key variables of osteoconduction involve architecture, surface texture, surface chemistry, pore size, and the prevalence of surface ligands. Finally, the CTP cells need to receive stimuli that induce progress toward a bone phenotype (i.e. differentiation). Osteoinductive stimuli can come from cytokines, growth factors, and extra-cellular matrix as well as biophysical signals in the graft environment (58) .
INCREASING CTP COUNT
CTPs are already used to augment graft sites in bone nonunions, fractures, and arthrodesis. Current methods include autologous cancellous bone and marrow grafts (59) (60) (61) (62) . Vascularized bone grafts provide autogenous CTPs as well. Several methods have been advanced to increase CTP concentration and prevalence over that in native tissue, principally using bone marrow as the cell source. One method, described by Muschler et al (60, 63) , utilizes the intrinsic property of marrow-derived CTPs to attach to certain implantable surfaces. This serves as a means for concentration and selection of cells. "Selective Retention" is achieved by passing an anticoagulated suspension of marrow cells through a porous matrix. Over 90% of CTPs can be retained, resulting in both concentration and retention as well as removing nonadherent WBCs and RBCs. This technology is now used clinically intraoperatively in the US.
Concentration of CTPs based on density separation using a centrifuge has also been applied clinically, first by Connolly et al (64, 65) in the treatment of nonunions. In a recent study, Hernigou (32) used a centrifuge to concentrate autologous bone marrow aspirates from the iliac crest. These were percutaneously injected into an atrophic tibial diaphyseal nonunion site. He found that the efficacy of these injections was related to the number of CTPs in the graft. The fifty-three patients with successful bone unions received grafts that contained greater than 1500 progenitors per cubic centimeter and an average total of 54,962 ± 17,431 progenitors. The seven patients who experienced non-union received 634 ± 187 progenitors per cubic centimeter and an average total of 19,324 ± 6843 progenitors. The concentration and total number of CTPs injected in the nonunion group were significantly lower (p =0.001 and p<0.01, respectively) than those in the patients who obtained bone union. Using computerized tomography at four months, they also demonstrated a positive correlation between the number and concentration of CTPs and the volume of the healing callus (32) .
CONCLUSION
The future of stem cells in orthopedic treatment and management requires an understanding of the factors affecting CTP populations. Improving knowledge of the biology of CTPs and improving the ability to harvest, analyze, and manipulate these cells present surgeons with the opportunity to harness the capacity of these cells for targeted modulation of regeneration and repair of skeletal tissues. The attachment, migration, proliferation, differentiation, and survival of these osteogenic cells can be influenced and modulated by selected bioactive molecules or therapeutics. The capacity to design specialized matrices that act as conductive scaffolds with defined structures, customized surface chemistries, and controlled degradation properties creates further opportunities to optimize the delivery and transplantation of highly selected osteogenic regenerative cells. Stem cell solutions will potentially improve clinical outcomes, the quality of life for orthopedic patients, and reduce the cost of effective care in many settings.
